For research use only. Not for therapeutic Use.
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma[1][2][3].
Anrukinzumab (IMA-638; 10 mg/kg; intravenous infusion; single) reduces lung inflammation in cynomolgus monkey model of lung inflammation[1].
| Catalog Number | I042175 |
| CAS Number | 910649-32-0 |
| Purity | ≥95% |
| Reference | [1]. Bree A, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol. 2007 May;119(5):1251-7. [2]. Reinisch W, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 2015 Jun;64(6):894-900. [3]. Elias JA, et al. IL-13 in asthma. The successful integration of lessons from mice and humans. Am J Respir Crit Care Med. 2011 Apr 15;183(8):957-8. |
